 |
Sign up for our newsletter!
Become a member! |
|
Invited Talk |
|
Technical aspects of translational imaging in pharma drug development process
Dr. Gudrun Zahlmann
Abstract The clinical drug development process relies on high quality data that describe the pharmacological and clinical effects of novel drugs. In the best case this will be validated quantitative biomarkers. One of the most promising biomarkers is molecular and medical imaging. To be used to its full capacity several challenges have to be faced. Data quality assurance and control, effective data transfer mechanisms, standardization of imaging processes to assure reliable quantitative results and advanced image analysis algorithms are some aspects that will influence the use pattern for pharma decision making but will also pave the way of quantitative imaging in healthcare.
Biography Dr. Zahlmann is a Biomedical Engineer and Computer
Scientist by training. She received her Ph.D. on Biomedical Engineering
from TU Ilmenau, Germany. After working in several positions in academic
institutions she joined Siemens Healthcare in 2000 working on
sustainable Healthcare IT solutions in novel application fields. Since
2009 she is working at Roche as manager imaging infrastructure in the
Global Imaging Sciences group. Dr. Zahlmann has published numerous
scientific publications in peer reviewed journals and holds more than 40
patents. She is member of IEEE EMBS. |
|
Volker Koch, 12/2009 |